A Multi-Centered Randomized Phase II Study Comparison of Single-Agent Carboplatin Vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer
Latest Information Update: 25 Feb 2025
Price :
$35 *
At a glance
- Drugs Everolimus (Primary) ; Carboplatin
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 19 Feb 2025 Status changed from active, no longer recruiting to completed.
- 16 Feb 2024 Planned End Date changed from 1 Jan 2024 to 1 Mar 2025.
- 16 Feb 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Mar 2025.